Menu
← Oncology Approval Tracker
FDA DECISION ·
Unloxcyt
cosibelimab-ipdl · Checkpoint Therapeutics
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with metastatic or locally advanced cutaneous squamous cell carcinoma for whom curative surgery or radiation is not an option.
LAMPGEN ANALYSIS
Why it matters
This PD-L1 antibody adds an option for advanced cutaneous squamous cell carcinoma when curative local treatment is unsuitable.
What research teams should watch
Document the multidisciplinary rationale for foregoing surgery or radiation and standardize assessment of external lesions.
PRIMARY RECORDS